Analgesia Clinical Trial
Official title:
Magnesium Sulphate Versus Fentanyl: Effects on the Quality of Bier Block: Double Blind Placebo Controlled Trial
Verified date | May 2020 |
Source | Assiut University |
Contact | Esam Taher, MD |
Phone | 01002228905 |
ehamed[@]gmail.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Intravenous regional anesthesia is one of the well-known techniques of regional anesthesia
for short surgical operations on the upper and lower limbs. It was first introduced back in
1908. Later on it was popularized even more for the same purpose by using two tourniquets to
isolate an exsanguinated extremity then injection of local anesthesia. It was proved over
time to be safe and effective with minimal side effects and complications.
Magnesium sulfate (MgSO4) has been used over the 20th century for prevention and treatment of
pre-eclamptic and eclampsia seizures during pregnancy because of its superior safety profile
over other drugs used for the same purpose. The specific mechanisms of action of magnesium
sulfate still unclear but are probably multi-factorial. It may act as a vasodilator on
peripheral as well as cerebral vasculature, to decrease peripheral vascular resistance and/or
relieve vasoconstriction. Additionally, it may also protect the blood-brain barrier and limit
cerebral edema formation, or it may also act as a central anticonvulsant.
Fentanyl; was first introduced back in 1990 for palliative use as fentanyl patch. Few years
later, it became available in different forms of administration being highly lipophilic. Few
years later it became the most widely used synthetic opioid in medicine. It is an opioid
analgesic with a rapid onset and short duration of action. It is a potent μ-opioid receptor
pure agonist. Fentanyl is 50 to 100 times more potent than morphine. Fentanyl has a
relatively wide therapeutic index, which makes it a very safe surgical anesthetic drug when
monitored carefully.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | August 31, 2020 |
Est. primary completion date | August 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - scheduled for short surgical procedures (30 - 60 minutes) distal to elbow - age 18-55 years old - ASA I - II - both genders - average weight BMI (25 - 35). Exclusion Criteria: - seizure diseases - allergy to the used medicine - local infection - patients with sickle cell anemia, Raynaud's disease, scleroderma, myasthenia gravis, significant cardiac or hepatic diseases. |
Country | Name | City | State |
---|---|---|---|
Egypt | Assiut University Hospital | Assiut |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | VAS score | Onset of tourniquet pain after deflating proximal tourniquet. VAS consists of a straight line with the endpoints defining extreme limits WHERE 0='no pain AND 10= severe pain. | 2 hours | |
Secondary | 3-point scale for motor function | 0: normal motor function, 1: reduced motor strength but able to move fingers, 2: complete motor block | 6 hours | |
Secondary | 3-point scale for sensory function | 0: normal sensation, 1: loss of sensation of cold (analgesia), 2: loss of sensation of touch (anesthesia). | 6 hours | |
Secondary | Total Supplement Analgesia | Total dose of pethidine 10 mg increments that will be used when the patients experience tourniquet pain >3 VAS. | 24 hours | |
Secondary | Complications | Number of patients with any intraoperative or postoperative complications will be recorded and treated. | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05534230 -
Dexmedetomidine for Pain Reduction in CABG
|
N/A | |
Recruiting |
NCT06275698 -
HONEY for the Treatment of POst-Tonsillectomy Pain
|
N/A | |
Recruiting |
NCT04436224 -
Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation
|
Phase 4 | |
Not yet recruiting |
NCT04548323 -
Hypoalgesic Effects of Walking and Running Imagined
|
||
Completed |
NCT06054945 -
Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
|
||
Completed |
NCT04394481 -
Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery
|
Phase 4 | |
Completed |
NCT04690647 -
The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement.
|
N/A | |
Completed |
NCT05034601 -
ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure
|
N/A | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05454202 -
Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
|
||
Recruiting |
NCT04554186 -
Serratus Anterior Plane Block Versus Thoracic Paravertebral Block.
|
N/A | |
Not yet recruiting |
NCT06393777 -
Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion
|
N/A | |
Suspended |
NCT04860635 -
Safety of F14 Following Total Knee Replacement
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04519463 -
The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing
|
Early Phase 1 | |
Completed |
NCT02916342 -
Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks
|
Phase 4 | |
Completed |
NCT03206554 -
Local Infiltration Analgesia in Total Knee Arthroplasty
|
Phase 2 | |
Not yet recruiting |
NCT02549118 -
Tenoxicam for Intrapartum Analgesia
|
Phase 2 | |
Not yet recruiting |
NCT02190760 -
Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block.
|
N/A | |
Completed |
NCT01789606 -
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
|
Phase 3 | |
Completed |
NCT01299584 -
ULTIVA Post Marketing Surveillance
|
N/A |